In patients with advanced IDH-1-mutated CCA that progressed on standard chemotherapy, treatment with ivosidenib, a potent targeted inhibitor of mutated IDH-1, significantly improved PFS and overall survival with a favorable safety profile, after adjusting for crossover (5). Here, IDH1 is linked to cholangiocarcinoma.